Perioperative management of the recipient of the extended criteria cadaveric donor liver (ECDL): A metabolic approach

International Anesthesiology Clinics

Volumn 44, Issue 4, 2006, Pages 79-96

  Pretto Jr , Ernesto A ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANESTHETIC AGENT; ANTIOXIDANT; CALCIUM CHLORIDE; CYCLOSPORIN A; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FENOLDOPAM; FUROSEMIDE; IMMUNOSUPPRESSIVE AGENT; LOOP DIURETIC AGENT; MAGNESIUM; MANNITOL; PRESERVATION SOLUTION;

ANOXIA; CADAVER DONOR; CALCIUM HOMEOSTASIS; HUMAN; HYPERKALEMIA; ISCHEMIA; KIDNEY DISEASE; LIVER PRESERVATION; LIVER PROTECTION; LIVER TRANSPLANTATION; PERIOPERATIVE PERIOD; PH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RENAL PROTECTION; REPERFUSION INJURY; RESUSCITATION; REVIEW; RISK FACTOR;

CADAVER; HUMANS; LIVER; LIVER TRANSPLANTATION; PERIOPERATIVE CARE; TISSUE DONORS;

EID: 33749609312     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aia.0000210816.08158.63     Document Type: Review

References (81)

1. Workgroup on Expanded Criteria Organs for Liver Transplantation. New York State Department of Health and Workgroup. Liver Transplant. 2005;11:1184-1192.
2. De Carlis L, Colella G, Sansalone CV, et al. Marginal donors in liver transplantation: the role of donor age. Transplantation Proc. 1999;31:397-400.
3. Agnes S, Avolio AW, Magalini SC, et al. Marginal donors for patients on regular waiting lists for liver transplantation. Transplant Int. 1996;9(suppl 1):S469-S471.
4. OPTN. Liver-only National Data 2005: Organ Procurement and Transplantation Network. Accessed April 2006.
5. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-470.
6. Raia S, Nery JR, Mies S. Liver transplantation from live donors. Lancet. 1989;2:497.
7. Cherqui D, Lauzet JY, Rotman N, et al. Orthotopic liver transplantation with preservation of the caval and portal flows. Transplant. 1994;58:793-796.
8. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transplant. 2003;7:651-663.
9. Farmer DG, Amersi F, Kupiec-Weglinski J, et al. Current status of ischemia reperfusion injury in the liver. Transplant Rev. 2000;14:106-126.
10. Feng S, Bragg-Gresham JL, Dysktra DM, et al. Definitions and outcomes of transplants using expanded criteria donor livers. Hepatology. 2004;38(suppl 1):S6.
11. Pretto E, Lewis M, Chidiac G, et al. The impact of time of terminal condition on graft and patient survival in liver transplantation [abstract]. Liver Transplant. 2005;11:S241.
12. LeMasters JJ. Hypoxic, ischemic, and reperfusion injury to liver. In: Arias IM, Boyer JL, Chisari FV, et al, eds. Liver Biology and Pathobiology, 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2001.
13. Pretto E. Reperfusion Injury of the liver (review). Transplantation Proc. 1991;23:1912.
14. Clavien PA. Sinusoidal endothelial cell injury during hepatic preservation and reperfusion. Hepatology. 1998;28:281-285.
15. McKeown CMB, Edwards V, Phillips MJ, et al. Sinusoidal lining cell damage: the critical injury in cold preservation of liver allografts in the rat. Transplantation. 1988;46:178-191.
16. Hansen TN, Dawson PE, Brockbank KGM. Effects of hypothermia upon endothelial cells: mechanisms and clinical importance. Cryobiology. 1994;31:101-106.
17. Hohacka PW. Defense strategies against hypoxia and hypothermia. Science. 1986;231:234-241.
18. Gao WS, Takei Y, Marzi I, et al. Effects of Carolina rinse solution - a new strategy to increase survival time after orthotopic liver transplantation in rats. Transplantation. 1991; 52:417-424.
19. Sanchez-Urdazpal L, Goes GJ, Lemasters JJ, et al. Carolina rinse solution decreases liver injury during clinical liver transplantation. Transplantation Proc. 1993;25:1574-1575.
20. Zimmerman BJ, Granger DN. Mechanisms of reperfusion injury. Am J Med Sci. 1994;307:284-292.
21. Vrba J, Modriansky M. Oxidative burst of Kupffer cells: target for liver injury treatment. Biomed Papers. 2002;146:15-20.
22. Zar H, Pretto E. Postischemic hepatic lipid peroxidation, monitored by chemiluminescence, depends on duration of ischemia. Transplantation Proc. 1996;28:2980-2982.
23. Tsouflas G, Geller DA. NFkB in transplantation: friend of foe? Transplant Infect Dis. 2001;3:212-219.
24. Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation. 2002;9:161-175.
25. Pretto EA. Cardiac function after hepatic ischemia-anoxia and reperfusion injury: a new experimental model. Crit Care Med. 1991;19:1188-1194.
26. Chavko R, Khan AS, Darby JM. Chapter 249: Management of the brain-dead donor. In: Fink MP, Abraham E, Vincent JL, et al, eds. Textbook of Critical Care. 5th ed. Philadelphia, PA: Elsevier Saunders; 2005.
27. The critical pathway for the organ donor. Available at: www.unos.org.
28. Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549-556.
29. Bigelow WG, Lindsay WK, Greenwood WF. Hypothermia. Its possible role in cardiac surgery: an investigation of factors governing survival in dogs at low body temperatures. Ann Surg. 1950;132:849-866.
30. Marion DW, Penrod LE, Kelsey SF, et al. Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med. 1997;336:540-546.
31. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557-563.
32. Shiozaki T, Sugikoto H, Taneda M, et al. Effect of mild hypothermia on uncontrollable intracranial hypertension after severe head injury. J Neurosurg. 1993;79:363-368.
33. Marion DW, Penrod LE, Kelsey SF, et al. Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med. 1997;336:540-546.
34. Wang HE, Callaway CW, Peitzman AB, et al. Admission hypothermia and outcome after major trauma. Crit Care Med. 2005;33:1296-1301.
35. Vaquero J, Blei AT. Mild hypothermia for acute liver failure: a review of mechanisms of action [review]. J Clin Gastroenterol. 2005;39(4 suppl 2):S147-S157.
36. Jalan R, Olde Damink SW, Deutz NE, et al. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology. 2004;127:1338-1346.
37. Zar HA, Tanigawa K, Kim Y, et al. Mild therapeutic hypothermia for postischemic vasoconstriction in the perfused rat liver. Anesthesiology. 1999;90:1103-1111.
38. Nagano K, Gelman S, Bradley EL Jr, et al. Hypothermia, hepatic oxygen supply-demand, and ischemia reperfusion injury in pigs. Am J Physiol. 1990;258(6 Pt 1):G910-G918.
39. Chung KY, Jeong KB, Choi SH, et al. Prevention of primary non-function after canine liver allotransplantation: the effect of gadolinium chloride. Transplant Proc. 2004;36:1928-1930.
40. Salaris SC, Babbs CF, Voorhees WD III. Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. A potential new drug for attenuation of ischemia/reperfusion injury. Biochem Pharmacol. 1991;42:499-506.
41. Weigan MA, Plachky J, Thies JC, et al. N-acetylcysteine attenuates the increase in α-glutathione s-transferase and circulating ICAM-1 and VCAM-1 after reperfusion in humans undergoing liver transplantation. Transplantation. 2001;72:694-698.
42. Karwinski W, Soreide O. Allopurinol improves scavenging ability of the liver after ischemia reperfusion injury. Liver. 1997;17:139.
43. Pretto EA, Dorko K. Prevention of hepatic Ischemic injury-induced coronary vasoconstriction with mannitol or lazaroid (U74006F). Anesthesiology. 1991;75:A221.
44. Hua-Sheng X, Stevenson WC, Pruett TL, et al. Donor lazaroid pretreatment improves viability of livers harvested from non-heart beating rats. Am J Surg. 1996;171:113-117.
45. Brolese A, Bassanello U, Cillo FA, et al. Extreme marginal donor: severe hypothermia as a rare preservation condition for explantable organs - a case report. Transplantation Proc. 2003;35:1282-1284.
46. Sekela ME, Young JB, Short HD, et al. Multi-organ procurement utilizing cardiopulmonary bypass and profound hypothermic circulatory arrest. Clin Transplantation. 1991;5:318-321.
47. Jones PE. Portable cardiopulmonary bypass for heart-lung donor transplants. Perfusion. 1991;6:187-189.
48. Rudich SM, Arenas JD, Magee JC, et al. Extracorporeal support of the non-heart beating organ donor. Transplantation. 2002;73:158.
49. Valero R, Gracia-Valdecasas JC, Tabet P, et al. Hepatic blood flor and oxygen extraction ratio during normothermic recirculation and total body cooling as viability predictors in non-heart beating donor pigs. Transplantation. 1998;66:170-176.
50. Winter P, Kang V, eds. In: Hepatic Transplantation: Anesthetic and Perioperative Management. New York: Praeger; 1986.
51. Kang Y. In: Flye MW, ed. Principles of Organ Transplantation. Philadelphia: WB Saunders Company; 1989:216-225.
52. Nagano K, Gelman S, Parks D, et al. Hepatic circulation and oxygen supply-uptake relationships after hepatic ischemic insult during anesthesia with volatile anesthetics and Fentanyl in miniature pigs. Anesth Anal. 1990;70:53-62.
53. Tanaka K, Ludwig LM, Krokilowski BA, et al. Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury. Role of cyclooxygenase-2. Anesthesiology. 2004;100:525-531.
54. Hoetzel A, Leitz D, Schmidt R, et al. Mechanism of hepatic heme oxygenase-1 induction by isoflurane. Anesthesiology. 2006;104:101-109.
55. Eckardt KU. Renal failure in liver disease. Intensive Care Med. 1999;25:5-14.
56. Bilbao I, Charco R, Balsells J, et al. Risk of renal failure requiring dialysis after liver transplantation. Clin Transplant. 1998;12:123-129.
57. Ishtani M, Wilowski M, Stevenson W, et al. Outcome of patients requiring hemodialysis after liver transplantation. Transplantation Proc. 1993;25:1762-1763.
58. Pascual E, Gomez-Arnau J, Pensado A, et al. The incidence and risk of early acute renal failure in liver transplant patients. Transplantation Proc. 1993;25:1837.
59. Fraley DS, et al. Impact of acute renal failure on mortality in end-stage liver disease with or without transplant. Kidney Int. 1998;54:518-524.
60. van Valenberg PLJ, Hoitsma AJ, Tiggeler RGWL, et al. Mannitol as an indispensable constituent of an intraoperative hydration protocol for the preservation of acute renal function after cadaveric transplantation. Transplantation. 1987;44:784-788.
61. Tiggeler RG, Berden JH, Hoitsma AJ, et al. Prevention of acute tubular necrosis in cadaveric kidney transplantation by the combined use of mannitol and moderate hydration. Ann Surg. 1985;201:246-251.
62. Polson RJ, Park GR, Lindop MJ, et al. The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. Anaesthesia. 1987;42:15-19.
63. Swygert TH, Roberts LC, Valek TR, et al. The effect of intraoperative low-dose dopamine on renal function in liver transplant recipients. Anesthesiology. 1991;75:571-576.
64. Byrick RJ, Rose DK. Pathophysiology and prevention of acute renal failure: the role of the anaesthetist. Can J Anaesth. 1990;37(4 Pt 1):457-467.
65. Dlewati A, Lokhandwala MF. Dose-response analysis of the effects of fenoldopam, a dopamine-1 receptor agonist on renal function. Drug Dev Res. 1991;22:59-68.
66. Aggarwal S, Kang Y, Freeman J, et al. Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation. Transplantation Proc. 1987;19:54-55.
67. Nanashima A, Pillay P, Crawford M, et al. Analysis of postrevascularization syndrome after orthotopic liver transplantation: the experience of an Australian liver transplantation center. J Hepatobiliary Pancreat Surg. 2001;8:557-563.
68. Polak WG, Miyamoto S, Nemes BA, et al. Sequential and simultaneous revascularization in adult orthotopic piggyback liver transplantation. Liver Transplant. 2005;11:934-940.
69. Koelzow H, Gedney JA, Bauman J, et al. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg. 2002;94:824-829.
70. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized clinical trial. Crit Care Med. 2001;29:1860-1867.
71. Weinbroum A. Selective attenuation of acute lung ventilatory injury by methylene blue after liver ischemia reperfusion: a drug response study in an isolated perfused double organ model. Transplantation. 2001;72:385-392.
72. Schenk P, Mzdl C, Shahrzad R, et al. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med. 2000;133:701-706.
73. Bromley PN, Cottam SJ, Hilmi I, et al. Effects of intraoperative N-acetylcysteine in orthotopic liver transplantation. Br J Anaesth. 1995;75:352-354.
74. Thies JC, Koeppel TA, Lehmann T, et al. Efficacy of N-acetylcysteine as hepatoprotective agent in liver transplantation: an experimental study. Transplantation Proc. 1997;29:1326-1327.
75. Droge W, Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. FASEB J. 1997;11:1077-1089.
76. Yip L, Dart RC. A 20-hour treatment for acute acetaminophen overdose. N Engl J Med. 2003;348:2471-2472.
77. Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991;324:1852-1857.
78. Koeppel TA, Thies JC, Lehman T, et al. Improvement of hepatic microhemodynamics by N-acetylcysteine after warm ischemia. Eur Surg Res. 1996;28:270-277.
79. Regueira FM, Hernandez I, Sola JA, et al. Ischemic damage prevention by N-acetylcysteine treatment of the donor before liver transplantation. Transplantation Proc. 1997;29:3347-3349.
80. Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrastagent-induced reduction in renal function by N-acetylcysteine. N Engl J Med. 2000;343:180-184.
81. Pirenne J, Gunson H, Khaleef S, et al. Influence of ischemia-reperfusion injury on rejection after liver transplantation. Transplantation Proc. 1997;29:366-367.